141798-03-0

Basic information

• Product Name: 1,3-dihydro-1-(2-hydroxyphenyl)-4-hydroxy-2H-benzimidazol-2-one
• Synonyms: 1,3-dihydro-1-(2-hydroxyphenyl)-4-hydroxy-2H-benzimidazol-2-one
• CAS NO: 141798-03-0
• Molecular Weight: 242.234
• Mol File: 141798-03-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,3-dihydro-1-(2-hydroxyphenyl)-4-hydroxy-2H-benzimidazol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dihydro-1-(2-hydroxyphenyl)-4-hydroxy-2H-benzimidazol-2-one(141798-03-0)
• EPA Substance Registry System: 1,3-dihydro-1-(2-hydroxyphenyl)-4-hydroxy-2H-benzimidazol-2-one(141798-03-0)

Safety Data

• Hazardous Substances Data: 141798-03-0(Hazardous Substances Data)

Usage

Chemical class

Benzimidazole derivative

Target enzyme

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

Enzyme function

Conversion of cortisone to cortisol

Potency

Potent inhibitor of 11β-HSD1

Selectivity

Selective inhibitor of 11β-HSD1

Therapeutic applications

Metabolic disorders (type 2 diabetes, obesity), inflammatory and autoimmune diseases

Mechanism of action

Modulation of glucocorticoid metabolism

Potential use

Development of new pharmaceuticals targeting metabolic, inflammatory, and autoimmune conditions

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 1226-63-7 1,3-bis(2-methoxyphenyl)urea 
• 141798-94-9 1,3-dihydro-1-(2-methoxyphenyl)-4-methoxy-2H-benzimidazol-2-one 

Relevant articles and documents

Benzimidazole derivatives, their preparation and use

A compound having the formula STR1 wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched;X is O, S, NCN;Y is O, S;R 4, R 5, R 6 and R 7 independently of each other are hydrogen, halogen, CF 3, NO 2, NH 2, OH, C 1-6 -alkoxy, C( O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl;R 11 is hydrogen, halogen, NO 2 or SO 2 NR''R"" wherein R'' and R"" independently are hydrogen or C 1-6 -alkyl;R 13 is hydrogen, halogen, phenyl, CF 3, NO 2 ;R 12 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;pharmaceutical compositions thereof,and a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above indicated, are disclosed.